lovastatin

lovastatin
IUPAC name	(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate
Width	200
Tradename	Mevacor, others
Drugs.com	monograph, lovastatin
MedlinePlus	a688006
Routes of administration	By mouth
Bioavailability	<5%
Protein bound	>95%
Metabolism	Liver (CYP3A4)
Elimination half-life	1.1–1.7 hours
Excretion	Feces (83%), urine (10%)
CAS number	75330-75-5
PubChem	53232
DrugBank	DB00227
ChemSpiderID	48139
UNII	9LHU78OQFD
KEGG	D00226
ChEBI	6431
ChEMBL	148
ATC prefix	C10
ATC suffix	AA02
Legal AU	S4
Legal CA	Rx-only
Legal UK	POM
Legal US	Rx-only
Legal EU	Rx-only
Legal status	Rx-only

lovastatin is a naturally occurring statin medication derived from the fungus Aspergillus terreus. It was the first statin approved for clinical use by the Food and Drug Administration in 1987, marketed under the brand name Mevacor. This lipid-lowering agent works by inhibiting HMG-CoA reductase, a key enzyme in the mevalonate pathway responsible for cholesterol synthesis. Its discovery and development marked a pivotal advancement in the prevention and management of atherosclerotic cardiovascular disease.

History and development

The discovery originated from the research of Akira Endo at the Sankyo Company in Japan, who was screening microbial extracts for cholesterol-lowering activity. Endo isolated a potent inhibitor, mevastatin, from the fungus Penicillium citrinum in the early 1970s. Concurrently, researchers at Merck & Co. led by Alfred Alberts and P. Roy Vagelos identified a similar compound from Aspergillus terreus, which was developed into the first commercially available statin. The approval of lovastatin by the Food and Drug Administration followed extensive clinical trials, including the landmark Expanded Clinical Evaluation of Lovastatin study. This development revolutionized the pharmaceutical approach to treating hypercholesterolemia and significantly influenced subsequent drug discovery efforts at institutions like the University of Texas Southwestern Medical Center.

Medical uses

It is primarily indicated as an adjunct to diet for the reduction of elevated total cholesterol and low-density lipoprotein levels in patients with primary hypercholesterolemia. It is also used to slow the progression of coronary atherosclerosis in patients with coronary heart disease. Clinical guidelines from the American College of Cardiology and the American Heart Association support its use for both primary and secondary prevention of atherosclerotic cardiovascular disease. Its efficacy in reducing major adverse cardiac events was demonstrated in studies such as the Air Force/Texas Coronary Atherosclerosis Prevention Study.

Mechanism of action

As a prodrug, it is hydrolyzed in the liver to its active β-hydroxyacid form. This active metabolite competitively inhibits the enzyme HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate, the rate-limiting step in the cholesterol biosynthetic pathway. This inhibition depletes intracellular cholesterol stores, leading to the upregulation of LDL receptor gene expression via the SREBP pathway on hepatocytes. The increased number of LDL receptors on the surface of liver cells enhances the clearance of apolipoprotein B-containing lipoproteins, such as LDL cholesterol, from the bloodstream.

Adverse effects

Common adverse reactions include myalgia, dyspepsia, constipation, and flatulence. The most serious potential risk is rhabdomyolysis, a severe form of myopathy that can lead to acute kidney injury; this risk is increased with concomitant use of drugs that inhibit the CYP3A4 enzyme, such as cyclosporine, itraconazole, and certain protease inhibitors. Other notable effects can include elevated liver transaminases and, rarely, immune-mediated necrotizing myopathy. Monitoring recommendations from the Food and Drug Administration include periodic assessment of creatine kinase and alanine transaminase levels.

Chemistry and pharmacokinetics

Chemically, it is a polyketide lactone derived from a hexahydronaphthalene ring system. It is a white, crystalline powder that is insoluble in water but soluble in organic solvents like chloroform and dimethyl sulfoxide. After oral administration, it undergoes extensive first-pass metabolism in the liver, primarily by the CYP3A4 isoenzyme, resulting in a low systemic bioavailability of less than 5%. Its metabolites are excreted predominantly via the bile into the feces, with a small percentage eliminated in the urine.

Biosynthesis and production

The natural production occurs through a fungal polyketide synthase pathway in Aspergillus terreus. The biosynthesis involves the iterative condensation of acetyl-CoA and malonyl-CoA units by a large enzymatic complex, followed by cyclization and tailoring reactions including oxidation and methylation. For commercial pharmaceutical production, it is manufactured via controlled fermentation processes using high-yielding strains of Aspergillus terreus in large-scale bioreactors. Subsequent downstream processing involves extraction, purification, and formulation into tablets, a process optimized by companies like Merck & Co. following principles of industrial microbiology.

Category:Drugs